Oncology

We are determined to create a world where more cancer patients can become cancer survivors.

Cancer Doesn’t Care. But We Do.

With an estimated 28 million new cancer diagnoses expected worldwide each year by 20401, we know we must strive to maximize the impact of our treatments and pioneer novel medicines.
Cancer Doesn’t Care. But We Do.

Our Focus

Our work in oncology is driven by the belief that we can improve the futures of people living with cancer. Our science of cancer is opening up new possibilities and sparking discovery to explore the full potential of promising mechanisms designed to hit cancer at its core.

Learn more about our R&D focus in oncology

Key disease areas

Key disease areas

We are focused on where we believe we can make the biggest difference based on our heritage, expertise and understanding of certain tumor types. Enhanced through strategic collaborations and direct input from patients and caregivers, we infuse this across every aspect of the treatment development journey with the aim of delivering life-changing treatments that will transform care for people now, and for the future.

Bladder Cancer

Our maintenance therapy for this disease was the first in decades to advance the treatment paradigm for patients with advanced bladder cancer.

  1. Learn more

Colorectal Cancer

For over two decades our treatment has been a leader in the continuum of care for people with metastatic colorectal cancer. With our deep expertise and commitment to the colorectal cancer community we are continuing our research in this area in the hope to help even more patients in the future.

  1. Learn more

Head & Neck Cancer

We have a long history in the treatment of head and neck cancer. Our precision medicine continues to be a backbone treatment for this disease.

Kidney Cancer

We were among the first to demonstrate efficacy of an immunotherapy combined with a tyrosine kinase inhibitor in advanced kidney cancer.

  1. Learn more

Lung Cancer

Our focused biomarker-driven research resulted in the approval of our oral MET inhibitor for advanced lung cancer harboring METex14 skipping alterations.

  1. Learn more

Rare Tumors

We introduced the first immunotherapy for the treatment of patients with metastatic Merkel cell carcinoma, a rare skin cancer that until that point had seen little innovation in treatment.

  1. Learn more

Investigative Tumors

Our R&D approach maximizes our expertise by focusing on synergies across our pipeline and advancing assets with clear added value and differentiation for patients. While we aim to further improve on regimens, we are also advancing new therapies with promising mechanisms designed to hit cancer at its core including DNA Damage Response, Tumor Immunology, Oncogenic Signaling and Antibody-Drug Conjugates.

  1. Learn more

* These therapeutic areas are not available in the US & Canada.
If you want to learn more about our Healthcare business in these countries please visit the respective websites EMD Serono (US) and EMD Serono (Canada)

By {{ authorText(item) }}

{{ item.publicationDate }}

The Science of Cancer

Our animated series explains some of the hottest topics and terminology in cancer research.

  • News

    For the most up-to-date information, view our latest oncology news releases.

    Click here
  • Pipeline

    Learn more about our oncology pipeline.

    Click here
  • Embracing Carers®

    The Embracing Carers Initiative aims to recognize the role family—or unpaid—carers play in society and support them at each step in their caregiving journey.

    Learn more

References:
1 ACS Cancer Atlas 2023

US-NONO-00715 01/25